Balraj Singh, Ph.D.
Department of Breast Surgical Oncology, Division of Surgery
About Dr. Singh
The goal of our studies is to improve outcomes in the clinic. I work closely with Anthony Lucci, M.D., a breast surgical oncologist, who is developing innovative approaches to improve outcomes. He directs a multidisciplinary Breast Cancer Micrometastasis Research Program. Our laboratory-based research supports and complements patients-oriented research. Dr. Lucci and I are active participants in Morgan Welch Inflammatory Breast Cancer Program and Clinic at MD Anderson Cancer Center. Inflammatory breast cancer (IBC) accounts for only 2% to 6% of all cases of breast cancers, but it is a highly aggressive disease with a poor prognosis (5 year survival rate of 40%). IBC is characterized by rapid disease progression and early distant metastatic disease progression. There has been little change in overall survival rates in the last 30 years and there are no therapeutic regimens developed specifically for IBC. Inflammatory breast cancers can be classified into estrogen receptor-positive, HER2-positive, and triple-negative subtypes similar to non-IBC breast cancers, although they are overrepresented in the more aggressive subtypes. Our goal is to improve survival of IBC patients. In this regard, there is a pressing need for simple and reliable models for testing potential therapeutic drugs that accurately predict how drugs will act in cancer patients. This task is difficult because of constantly evolving nature of cancer, its genomic instability, and tumor heterogeneity. Our cell-based model that involves function-based selection of rare but adaptable cells that drive cancer, and testing therapies in long-term assays, will make the test results more predictive and have a major impact on drug development and cancer care in near future.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Surgical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Inflammatory Breast Cancer, breast cancer, triple-negative breast cancer, therapy-resistant cancer, tumor progression, metastasis, tumor heterogeneity, cancer metabolism, tumor adaptability, tumor evolution, metabolic adaptability, disseminated tumor cells, tumor cell quiescence, predictive assay development, cancer therapeutics.
Clinical Interests
Inflammatory breast cancer, triple-negative breast cancer, melanoma, resistant cancers, cancer evolution, preclinical models, therapy development.
Education & Training
Degree-Granting Education
| 1978 | Jawaharlal Nehru University, New Delhi, IN, Ph.D. in Cell Biology |
| 1976 | Jawaharlal Nehru University, New Delhi, IN, MPhil in Life Sciences |
| 1974 | G.B. Pant University of Ag. & Tech, Pantnagar, IN, M.S. in Biochemistry |
| 1971 | G.B. Pant University of Ag. & Tech, Pantnagar, IN, BS in Chemistry, Physics, Mathematics |
Postgraduate Training
| 1981-1983 | Postdoctoral Fellow, Roche Institute of Molecular Biology, Nutley, New Jersey |
| 1979-1981 | Research Associate, Washington University School of Medicine, St. Louis, Missouri |
| 1978-1979 | Research Fellowship, Jawaharlal Nehru University, New Delhi |
Experience & Service
Academic Appointments
Assistant Professor, Department of Surgical Oncology - Research, The University of Texas MD Anderson Cancer Center,, Houston, TX, 2004 - 2013
Assistant Professor, Department of Micheal E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 2001 - 2004
Associate Biochemist and Assistant Professor, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2000
Assistant Biochemist and Assistant Professor, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1992 - 1998
Assistant Biochemist, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1986 - 1992
Research Associate, Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, CA, 1983 - 1986
Institutional Committee Activities
Member, Steering Committee of the Graduate Program in Virology and Gene Therapy, 1997 - 2000
Member, Curriculum Committee of the Graduate Program in Molecular Pathology, 1997 - 2000
Honors & Awards
| 2007 | Best Overall Manuscript Award for "Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells", The Association of Academic Surgery, 2007 AAS Annual Meeting, Phoenix, AZ |
| 1998 | Dean's Excellence Award, GSBS, UTHSC/MDACC |
| 1974 | Council of Scientific and Industrial Research (New Delhi, India) Junior and Senior Research Fellowships |
| 1969 | College Merit Certificate |
Selected Publications
Peer-Reviewed Articles
- Singh B, Sarli VN, Milligan RD, Kinne HE, Shamsnia A, Washburn LJ, Addanki S, Lucci A. Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer. Cancers 15(7):2036, 2023. e-Pub 2023. PMID: 37046697.
- Singh, B, Sarli, VN, Lucci, A. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers 14(11), 2022. e-Pub 2022. PMID: 35681611.
- Singh B, Sarli VN, Lucci A. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers 14(11):2631, 2022. e-Pub 2022.
- Singh, B, Sarli, VN, Lucci, A. Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget 12(7):626-637, 2021. e-Pub 2021. PMID: 33868584.
- Singh B, Sarli VN, Kinne HE, Shamsnia A, Lucci A. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget 10(38):3681-3693, 2019. e-Pub 2019.
- Singh B, Sarli VN, Washburn LJ, Raythatha MR, Lucci A. A usable model of “decathlon winner” cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget 9(13):11071-11082, 2018. e-Pub 2018.
- Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS ONE 11(7):e0159072, 2016. e-Pub 2016.
- Singh B, Shamsnia A, Raythatha MR, Milligan RD, Cady AM, Madan S, Lucci A. Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. PLoS One 9(10):e109487, 2014. e-Pub 2014. PMID: 25279830.
- Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118(2):342-348, 2012. e-Pub 2012. PMID: 21717428.
- Singh B, Tai K, Madan S, Raythatha MR, Cady AM, Braunlin M, Irving LR, Bajaj A, Lucci A. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One 7(5):e3610, 2012. e-Pub 2012. PMID: 22570721.
- Singh B, Cook KR, Vincent L, Hall CS, Martin C, Lucci A. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 168(1):e39-49, 2011. e-Pub 2011. PMID: 20462604.
- Singh B, Irving LR, Tai K, Lucci A. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 164(2):235-243, 2010. e-Pub 2010. PMID: 20691996.
- Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14):3330-3337, 2010. e-Pub 2010. PMID: 20564098.
- Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27(4):233-240, 2010. e-Pub 2010. PMID: 20229045.
- Singh B, Irving LR, Tai K, Lucci A. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 164(2):235-243, 2010. e-Pub 2010.
- Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clin Cancer Res 15(21):6639-6648, 2009. e-Pub 2009. PMID: 19825949.
- Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61-68, 2009. e-Pub 2009. PMID: 18663571.
- Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231-6, 2009. e-Pub 2009. PMID: 19482312.
- Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-507, 2009. e-Pub 2009. PMID: 18327638.
- Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147(2):240-6, 2008. e-Pub 2008. PMID: 18498876.
- Singh B, Vincent L, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res 140(2):220-226, 2007. e-Pub 2007. PMID: 17418864.
- Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789-3796, 2007. e-Pub 2007. PMID: 17213821.
- Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res 134(1):44-51, 2006. e-Pub 2006. PMID: 16678856.
- Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 131(2):267-75, 2006. e-Pub 2006. PMID: 16457848.
- Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26(5):1393-9, 2005. e-Pub 2005. PMID: 15809733.
- Pham CD, Vuyyuru VB, Yang Y, Bai W, Singh B. Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos. Oncogene 18:4287-94, 1999. e-Pub 1999. PMID: 10439036.
- Liu H, Vuyyuru VB, Pham CD, Yang Y, Singh B. Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association. Oncogene 18:3461-70, 1999. e-Pub 1999. PMID: 10376524.
- Yang Y, Pham CD, Vuyyuru VB, Liu H, Arlinghaus RB, Singh B. Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites. A dominant inhibitory role of serine 25 phosphorylation on Mos protein kinase. J Biol Chem 273:15946-53, 1998. e-Pub 1998. PMID: 9632642.
- Yang Y, Pham CD, Arlinghaus RB, Khillan JS, Singh B. Elevated level of cyclin D1 in mos-transformed cells. Int J Oncol 12:1199-202, 1998. e-Pub 1998. PMID: 9538150.
- Ling YH, Yang Y, Tornos C, Singh B, Perez-Soler R. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58:3633-40, 1998. e-Pub 1998. PMID: 9721872.
- Pham CD, Rungta M, Chandler DS, Yang Y, Arlinghaus RB, Rajagopalan S, Schwartz MR, Singh B. Essential role of c-Mos in eggs: reduced fertility and ovarian neoplasm in antisense mos transgenic mice. Int J Gynecol Cancer 7:314-317, 1997. e-Pub 1997.
- Tsui LV, Ramagli LS, Gao C, Pham CD, Pandita TK, Arlinghaus RB, Singh B. The biological effects of antisense mos expression in fibroblasts. Int J Oncol 11:1171-1178, 1997. e-Pub 1997.
- Yang Y, Herrmann CH, Arlinghaus RB, Singh B. Inhibition of v-Mos kinase activity by protein kinase A. Mol Cell Biol 16:800-9, 1996. e-Pub 1996. PMID: 8622681.
- Gao C, Arlinghaus RB, Singh B. Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells. Oncogene 12:1571-6, 1996. e-Pub 1996. PMID: 8622874.
- Pham CD, Arlinghaus RB, Zheng CF, Guan KL, Singh B. Characterization of MEK1 phosphorylation by the v-Mos protein. Oncogene 10:1683-8, 1995. e-Pub 1995. PMID: 7731726.
- Lengye E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 11:2639-48, 1995. e-Pub 1995. PMID: 8545121.
- Bai W, Arlinghaus RB, Singh B. Association of v-Mos with soluble vimentin in vitro and in transformed cells. Oncogene 8(8):2207-12, 1993. e-Pub 1993. PMID: 8336943.
- Tsui LV, Ramagli LS, Singh B, Nash MA, Arlinghaus RB. Somatic cell expression of the mos proto-oncogene is cell cycle regulated: highest RNA expression in the G2 phase. Int J Oncology 2:493-502, 1993. e-Pub 1993.
- Hamelin R, Planchon P, Singh B, Arlinghaus RB. Inhibition of viral mos gene expression in transformed cells restricts cells cycle progression through G1 and G2 phases. Int J Oncology 1:513-523, 1992. e-Pub 1992.
- Bai W, Singh B, Yang Y, Arlinghaus RB. Evidence for interaction between v-Mos and a p34cdc2 isoform, p35cdk. Oncogene 7:1757-63, 1992. e-Pub 1992. PMID: 1323818.
- Singh B, Stocking C, Walker R, Yang YD, Ostertag W, Arlinghaus RB. v-mos proteins encoded by myeloproliferative sarcoma virus and its ts159 mutant. J Virol 66:1267-72, 1992. e-Pub 1992. PMID: 1309903.
- Bai W, Singh B, Yang Y, Ramagli LS, Nash M, Herzog NK, Arlinghaus RB. The physical interactions between p37env-mos and tubulin structures. Oncogene 7:493-500, 1992. e-Pub 1992. PMID: 1532247.
- Zhao X, Singh B, Batten B. The role of c-mos proto-oncogene in mammalian meiotic maturation. Oncogene 6:43-49, 1991. e-Pub 1991.
- Zhao X, Singh B, Arlinghaus RB. Inhibition of c-Mos protein kinase blocks mouse zygotes at the pronuclei stage. Oncogene 6:1423-1426, 1991. e-Pub 1991.
- Bai WL, Singh B, Karshin WL, Shonk RA, Arlinghaus RB. Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2. Oncogene 6:1715-23, 1991. e-Pub 1991. PMID: 1833715.
- Al-Bagdadi F, Singh B, Arlinghaus RB. Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase. Oncogene 5:1251-7, 1990. e-Pub 1990. PMID: 2168030.
- Singh B, al-Bagdadi F, Liu JX, Arlinghaus RB. Use of antipeptide antibodies to probe the catalytic activity of p37v-mos. Virology 178:535-42, 1990. e-Pub 1990. PMID: 2171192.
- Hamelin R, Honore N, Sergiescu D, Singh B, Gerfaux J, Arlinghaus RB. Reversion of the thermosensitive splicing defect of Moloney murine sarcoma virus ts110 by oversplicing of the viral RNA. J Virol 64:1378-1382, 1990. e-Pub 1990.
- Zhao X, Batten B, Singh B, Arlinghaus RB. Requirement of the c-Mos protein kinase for murine meiotic maturation. Oncogene 5:1727-1730, 1990. e-Pub 1990.
- Liu JX, Singh B, Wlodek D, Arlinghaus RB. Cell cycle-mediated structural and functional alteration of P85gag-mos protein kinase activity. Oncogene 5:171-8, 1990. e-Pub 1990. PMID: 2138725.
- Roy L, Singh B, Gautier J, Arlinghaus RB, Nordeen SK, Maller JL. The cyclin B2 component of MPF is a substrate for the c-mosxe proto-oncogene product. Cell 61:825-831, 1990. e-Pub 1990.
- Singh B, Arlinghaus RB. Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells. Virology 173:144-56, 1989. e-Pub 1989. PMID: 2554568.
- Singh B, Wittenberg C, Hannink M, Reed SI, Donoghue DJ, Arlinghaus RB. The histidine-221 to tyrosine substitution in v-mos abolishes its biological function and its protein kinase activity. Virology 164:114-20, 1988. e-Pub 1988. PMID: 2966489.
- Singh B, Herzog NK, Liu J, Arlinghaus RB. p37mos encoded by the HT-1 strain of Moloney murine sarcoma virus has an associated protein kinase activity. Oncogene 3:79-85, 1988. e-Pub 1988.
- Herzog NK, Singh B, Elder J, Lipkin I, Trauger RJ, Millette CF, Goldman DS, Wolfes H, Cooper GM, Arlinghaus RB. Identification of the protein product of the c-mos proto-oncogene in mouse testes. Oncogene 3:225-9, 1988. e-Pub 1988. PMID: 2970613.
- Singh B, Goldman R, Hutton L, Herzog NK, Arlinghaus RB. The P55 protein affected by v-mos expression is vimentin. J Virol 61:3625-9, 1987. e-Pub 1987. PMID: 2822968.
- Singh B, Wittenberg C, Reed SI, Arlinghaus RB. Moloney murine sarcoma virus encoded p37mos expressed in yeast has protein kinase activity. Virology 152:502-506, 1986. e-Pub 1986.
- Singh B, Sparrow JT, Hedge AM, Arlinghaus RB. Expression for the v-mos gene alters a Mr 55,000 protein during acute infection by Moloney murine sarcoma virus. Proc Natl Acad Sci USA 83:3629-3633, 1986. e-Pub 1986.
- Escobedo J, Singh B, Dina D, Arlinghaus RB. Temperature dependent cytocidal effects of Moloney murine sarcoma virus. Virus Res 6:75-84, 1986. e-Pub 1986.
- Singh B, Hannink M, Donoghue DJ, Arlinghaus RB. p37mos associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos. J Virol 60:1148-1152, 1986. e-Pub 1986.
- Gallick GE, Sparrow JT, Singh B, Maxwell SA, Stanker LH, Arlinghaus RB. Recognition of Mos related proteins with an antiserum to a peptide of the v-mos gene product. J Gen Virol 66:945-955, 1985. e-Pub 1985.
- Roy MK, Singh B, Ray BK, Apirion D. Maturation of 5S rRNA: Ribonuclease E cleavages and their dependence on precursor sequences. Eur J Biochem 131:119-127, 1983. e-Pub 1983.
- Singh B, Thornton GB, Roy J, Talib S, De BP, Banerjee AK. Frequent intragenic transcription termination within the N gene of vesicular stomatitis virus. Virology 122:239-250, 1982. e-Pub 1982.
- Singh B, Apirion D. Primary and secondary structure in a precursor of 5S rRNA. Biochim Biophys Acta 698:252-259, 1982. e-Pub 1982.
- Ray BK, Singh B, Roy MK, Apirion D. Ribonuclease E is involved in the processing of 5S from a number of rRNA transcription units. Eur J Biochem 125:283-289, 1982. e-Pub 1982.
- Biswas M, Singh B, Ra, YP, Datta A. Turnover of inducible N-acetylglucosamine catabolic enzymes in Candida albicans. Ind J Exp Biol 20:829-834, 1982. e-Pub 1982.
- Singh B, Biswas M, Datta A. Inducible N-acetylgluosamine binding protein in yeasts. J Bacteriol 114:1-6, 1980. e-Pub 1980.
- Rai YP, Singh B, Elango N, Datta A. Purification and some properties of inducible N-acetylglucosamine kinase from Candida albicans. Biochim Biophys Acta 614:350-356, 1980. e-Pub 1980.
- Singh B, Guptaroy B, Hasan G, Datta A. Inhibitory effect of glucose and adenosine 3', 5'-monophosphate on the synthesis of inducible N-acetylglucosamine catabolic enzymes in yeast. Biochim Biophys Acta 632:345-353, 1980. e-Pub 1980.
- Singh, B, Datta, A. Regulation of glucosamine-6-phosphate deaminase synthesis in yeast. BBA - General Subjects 583(1):28-35, 1979. e-Pub 1979. PMID: 369615.
- Singh B, Datta A. Regulation of N-acetylglucosamine uptake in yeast. Biochim Biophys Acta 557:248-258, 1979. e-Pub 1979.
- Singh B, Datta A. Induction of N-acetylglucosamine catabolic pathway in spheroplasts of Candida albicans. Biochem J 178:427-431, 1979. e-Pub 1979.
- Biswas M, Singh B, Datta A. Induction of N-acetylmannosamine catabolic pathway in yeast. Biochim Biophys Acta 585:535-542, 1979. e-Pub 1979.
- Singh B, Datta A. Regulation of glucosamine-6-phosphate deaminase synthesis in yeast. Biochim Biophys Acta 583:28-35, 1979. e-Pub 1979.
- Singh, B, Datta, A. Glucose repression of the inducible catabolic pathway for N-acteylglucosamine in yeast. Biochem Biophys Res Commun 84:58-64, 1978. e-Pub 1978.
Invited Articles
- Singh B. The mos oncogene and its expression in germ cells. Cancer Bulletin 40:310-315, 1988. e-Pub 1988.
Other Articles
- Addanki, S, Meas, S, Sarli, VN, Singh, B, Lucci, A Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. International journal of molecular sciences 23(14), 2022. PMID: 35887191.
- Singh B, Sarli VN, Milligan RD, Kinne HE, Shamsnia A, Washburn LJ, Lucci A Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancer (Preprint). Research Square, 2022.
- Singh, B, Sarli, VN, Kinne, HE, Shamsnia, A, Lucci, A Erratum. Oncotarget 13(1):1272, 2022. PMID: 36395366.
- Lang JE, Hall CS, Singh B, Lucci A Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? (Review). Expert Rev Anticancer Ther 7(10):1463-1472, 2007. PMID: 17944570.
- Lang JE, Hall CS, Singh B, Lucci A Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? (Review). Expert Rev Anticancer Ther 7(10):1463-1472, 2007. PMID: 17944570.
- Singh B, Lucci A Role of cyclooxygenase-2 in breast cancer. J Surg Res 108(1):173-9, 2002. PMID: 12472107.
- Singh B, Arlinghaus RB Mos and the cell cycle. Prog Cell Cycle Res 3:251-9, 1997. PMID: 9552420.
- Singh B, Arlinghaus RB The mos proto-oncogene product: its role in oocyte maturation, metaphase arrest, and neoplastic transformation. Mol Carcinog 6:182-9, 1992. PMID: 1332729.
Abstracts
- Singh B, Sarli VN, Lucci A. Modeling evolutionary fitness in resistant cancers based on a common adaptability trait. AACR Annual Meeting, San Diego, CA, April 05-10, 2024 (Cancer Research), 2024. e-Pub 2024.
- Singh B, Sarli VN, Lucci A. Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer. AACR Annual Meeting, San Diego, CA, April 24 - April 29, 2020, 2020. e-Pub 2020.
- Singh B, Sarli VN, Lucci A. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. AACR Annual Meeting, Atlanta, GA, March 29 - April 3, 2019, 2019. e-Pub 2019.
- Singh B, Sarli VN, Lucci A. Metabolically adaptable cancer cells as a usable cell culture model of rapidly progressing poor-prognosis minimal residual disease in triple-negative breast cancer: Mechanistic insights and evaluation of a potential therapy. AACR Special Conference: Cancer Dormancy and Residual Disease, Montreal, QC, Canada, June 19-22, 2018, 2018. e-Pub 2018.
- Singh B, Sarli VN, Lucci A. Modeling “decathlon winner” cancer cells that drive therapy resistance and metastasis in triple-negative breast cancer. AACR Conference on Advances in Breast Cancer Research, Hollywood, CA, Oct 7-10, 2017, 2017. e-Pub 2017.
- Singh B, Sarli VN, Lucci A. Modeling “decathlon winner” cancer cells that drive therapy resistance and metastasis in triple-negative breast cancer. MDACC Cancer Symposium 2017: Cancer Metabolism, Oct 5-6, 2017, 2017. e-Pub 2017.
- Singh B, Sarli VN, Washburn LJ, Lucci A. A usable model of panresistant triple-negative breast cancer cells for discovering therapies that would halt recurrence and metastasis. Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference: The Future of Inflammatory Breast Cancer, Feb 11-12, 2017, 2017. e-Pub 2017.
- Singh, Washburn LJ, Kinne HE, Milligan RD, Sarli VN, Lucci A. Treatment with a Jumonji demethylase inhibitor JIB-04 sensitizes resistant breast cancer cells to chemotherapeutic drugs in an in vitro model of intrinsic resistance. San Antonio Breast Cancer Symposium Dec 6-10, 2016, 2016. e-Pub 2016.
- Singh B, Washburn LJ, Kinne HE, Sarli VN, Lucci A. A usable model of panresistant triple-negative breast cancer cells for discovering therapies that would halt cancer evolution. MD Anderson Cancer Center Symposium on Cancer Evolution, 2016. e-Pub 2016.
- Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important role of FTO in the survival of rare panresistant triple-negative Inflammatory Breast Cancer cells under a severe metabolic challenge. AACR Annual Meeting, New Orleans, LA, April 16-20, 2016, 2016. e-Pub 2016.
- Singh B, Milligan RD, Kinne HE, Shamsnia A, Lucci A. Highly adaptable triple-negative breast cancer cells as a suitable model for testing epigenetic therapies. AACR Annual Meeting, Philadelphia, PA, April 18-22, 2015, 2015. e-Pub 2015.
- Singh B, Shamsnia A, Milligan RD, Lucci A. Modeling the Roots of Aggressive Triple-negative Breast Cancer for Drug Discovery by Selecting Adaptable Metabolic State in vitro. Keystone Symposia Conference on Tumor Metabolism, Whistler, British Columbia, Canada, 2014. e-Pub 2014.
- Singh B, Shamsnia A, Raythatha MR, Lucci A. A new strategy for testing therapies to be effective against genome based drivers of triple-negative breast cancer. MD Anderson Cancer Center Symposium on Genomic Medicine, 2013. e-Pub 2013.
- Singh B, Shamsnia A, Raythatha MR, Lucci A. Developing a predictive cell-based assay for anti-cancer drug selection. AACR Annual Meeting, Washington, DC, April 6-10, 2013, 2013. e-Pub 2013.
- Singh B, Raythatha MR, Shamsnia A, Lucci A. Body-like enrichment of metastatic breast cancer cells in vitro for developing anti-cancer thrapies. Keystone Symposium on Tumor Metabolism, Keystone, CO, February 24 - March 1,, 2013. e-Pub 2013.
- Singh B, Raythatha MR, Shamsnia A, Lucci A. A new strategy for testing therapies to be effective against seemingly untreatable cancers. CTRC-AACR, San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-14,, 2013. e-Pub 2013.
- Singh B, Raythatha MR, Cady AC, Madan S, Tai K, Irving LR, Lucci A. In vitro selection of metastatic breast cancer cells based on their adaptability. AACR 103rd Annual Meeting, Chicago, IL, March 31 - April 4,, 2012. e-Pub 2012.
- Singh B, Cady AC, Raythatha MR, Lucci A. Developing a predictive in vitro assay for evaluating therapies against metastatic breast cancer. AACR 103rd Annual Meeting, Chicago, IL, March 31 - April 4,, 2012. e-Pub 2012.
- Singh B, Raythatha MR, Cady AC, Shamsnia A, Lucci A. Tackling tumor heterogeneity in inflammatory breast cancer by focusing on metabolically adaptable cancer cells. 3rd International Inflammatory Breast Cancer Congress, Philadelphia, PA, December 1-2,, 2012. e-Pub 2012.
- Lucci A, Singh B, Tai K, Madan S, Braunlin M, Irving LR, Bajaj A. In vitro selection of metastatic breast cancer cells. DOD BCRP Era of Hope Conference, Orlando, Florida, 2011. e-Pub 2011.
- Singh B, Tai K, Braunlin M, Madan S, Irving LR, Bajaj A, Lucci A. Selection of rare and novel breast cancer cell variants bassed on their plasticity of glutamine metalolism. AACR 102nd Annual Meeting, Orlando, Florida, 2011. e-Pub 2011.
- Singh B, Tai K, Irvin LR, Madan S, Lucci A. Lack of serum and attachment selects rare and potentially aggressive subpopulations of breast cancer cells (Accepted for Quick Shot Presentation). Annual Academic Surgical Congress, Huntington Beach, CA, 2011. e-Pub 2011.
- Singh B, Madan S, Braunlin M, Tai K, Irving L, Raythatha M, Lucci A. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. Poster presentation at the CPRIT Annual Conference, Austin, Texas, November 15-17, 2011. e-Pub 2011.
- Bhattacharyya A, Lodhi AK, Krishnamurthy S, Hall CS, Anderson AE, Kuerer HM, Bedrosian I, Singh B, Lucci A. Which is a better predictor of outcome in stage I-III breast cancer after neoadjuvant chemotherapy: microscopic disease in bone marrow or lymph nodes?. Presented at American Society of Breast Surgeons 12th Annual Meeting, Washingon, DC, April 27 - May 1, 2011. e-Pub 2011.
- Lucci A, Krishnamurthy S, Lodhi A, Bhattacharyya A, Hall C, Anderson A, Bedrosian I, Singh B, Kuerer H. Microscopic disease in blood and bone marrow predicts survival in early stage breast cancer. Poster Presentation at the 2011 SABCS, San Antonio, Texas, December 6 - 10, 2011. e-Pub 2011.
- Singh B, Tai K, Irvin L, Cook K, Lucci A. Selection of rate and novel breast cancer cell variants based on glutamine metabolism (Poster Presentation). San Antonio Breast Cancer Symposium, 2010. e-Pub 2010.
- Hall CS, Singh B, Tai K, Hicks LR, Lucci A. Zoledronate inhibits proliferation and invasion of inflammatory breast cancer cells. AACR 101st Annual Meeting, Washington, DC, 2010. e-Pub 2010.
- Singh B, Tai K, Cook KR, Irving LR, Lucci A. Differences in glutamine-dependence among breast cancer cell lines. AACR 101st Annual Meeting, Washington, DC, 2010. e-Pub 2010.
- Lucci A, Krishnamurthy S, Lodhi A, Hall C, Singh B. Disseminated tumor cells in histologic subtypes of Stage I-III breast cancer patients. 63rd SSO Annual Cancer Symposium, St. Louis, MO, 2010. e-Pub 2010.
- Singh B, Irving LR, Tai K, Cristofanilli M, Lucci A. Overexpression of cyclooxygenase-2 in celecoxib-resistant breast cancer cell lines. 5th Annual Academic Surgical Congress, San Antonio, TX, 2010. e-Pub 2010.
- Deleonardis C, Lodhi A, Le-Petross H, Singh B, Krishnamurthy S, Lucci A. Plemorphic calcifications, tumor markers and response to therapy. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Gainer S, Lodhi A, Krishnamurthy S, Jackson S, Hall C, Andreopoulou E, Singh B, Bedrosian I, Meric-Bernstam F, Kuerer H, Hunt K, Cristofanilli M, Lucci A. Predictors of persistent micrometastatic disease after neoadjuvant chemotherapy. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Singh B, Daniel C, Vincent L, Lucci A. Cyclooxygenase-2 expression up-regulates EGFR protein level and alters glucose metabolism in MCF10A breast epithelial cell line. 100th Annual AACR Meeting, Denver CO, 2009. e-Pub 2009.
- Silberfein EJ, Singh B, Martin C, Cook KR, Lucci A. Evaluation of androgen receptor as a therapeutic target in breast cancer (Oral Presentation). 4th Annual Academic Surgical Congress, Fort Meyers, FL, 2009. e-Pub 2009.
- Mosalpuria K, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cristonfanilli M, Lucci A. Correlation of COX-2 expression with Stage I-III triple receptor negative breast cancer (Poster Presentation). 61st Annual SSO Cancer Symposium, Chicago, Illinois, 2008. e-Pub 2008.
- Cook KR, Singh B, Vincent L, Berry A, Multani AS, Lucci A. Cyclooxygenase-2 induces genomic instability BCL2 expression, doxorubicin resistance and altered cancer initiating cell phenotype in MCF7 breast cancer cells (Poster Presentation). 3rd. Annual Academic Surgical Congress, Huntington Beach, California, 2008. e-Pub 2008.
- Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cook K, Mosalpuria K, Cristofanilli M. COX-2 expression correlates with bone marrow micrometastasis in patients with stage I-III breast cancer. Era of Hope Department of Defense Breast Cancer Research program, Baltimore, MD, 2008. e-Pub 2008.
- Singh B, Cook KR, Vincent L, Hall C, Martin C, Lucci A. Role of COX-2 in bone marrow micrometastasis and cancer initiating cell phenotype in breast cancer. Joint Metastasis Research Society-AACR Conference on Metastasis, Vancouver, Canada, 2008. e-Pub 2008.
- Lang JE, k M, Cristofanilli M, Krishnamurthy S, Rueben J, Singh B, Bedorsian I, Meric-Bernstam F, Lucci A. Primary tumor characteristics and lymph node status fail to predict presence of circulating tumor cells in patients with operable breast cancer, 60th Annual SSO Cancer Symposium, Washington, D.C. Ann Surg Oncol 14:160-180, 2007. e-Pub 2007.
- Huang EH, Singh B, Vincent L, Cristofanilli M, Mosalpuria K, Caimiao W, Lucci A. Inhibition of primary tumor growth and distant metastasis with a CXCR4 antagonist in a mouse model of breast cancer (Oral Presentation). American Association for Cancer Research, Los Angeles, CA, 2007. e-Pub 2007.
- Singh B, Vincent LE, Berry JA, Multani S, Lucci A. Cyclooxygenase-2 perturbs DNA damage checkpoint signaling in MCF10A breast epithelial cells (Poster Presentation). American Association for Cancer Research, Los Angeles, California, 2007. e-Pub 2007.
- Vincent LE, Singh B, Berry JA, Multani S, Lucci A. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells (Oral Presentation). 2nd Annual Academic Surgical Congress, Phoenix, Arizona, 2007. e-Pub 2007.
- Rourke L, Lang JE, Mosalpria K, Yi M, Cristofanilli M, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. Impact of neoadjuvant chemotherapy on presence of circulating tumor cells and disseminated tumor cells in operable breast cancer (Poster Presentation). American Society of Breast Surgeons, Phoenix, Arizona, 2007. e-Pub 2007.
- Huang EH, Singh B, Vincent L, Cristofanilli M, Mosalpuria K, Caimiao W, Lucci A. CXCR4 antagonist for breast cancer (Accepted for Oral Presentation). American Association for Cancer Research, Los Angeles, California, 2007. e-Pub 2007.
- Lucci A, Singh B, Berry JA, Shoher A. COX-2 inhibitor prevents metastasis to bone in a mouse model of breast cancer (Oral Poster Presentation). Academic Surgical Congress, San Diego, California, 2006. e-Pub 2006.
- Berry JA, Singh B, Vincent LE, Lucci A. Involvement of IL-8 in COX-2 mediated bone metastases from breast cancer (Oral Presentation). Association for Academic Surgery Annual Meeting, San Diego, California, 2006. e-Pub 2006.
- Singh B, Sarli VN, Lucci A. A cell culture model of resistant cells in solid cancers that opportunistically switch between proliferation and quiescence. AACR Annual Meeting, Orlando, FL, April 14-19, 2023.
Book Chapters
- Singh, B, Mujoo, K, Lucci, A. Therapeutics of Oxidative Stress and Stemness in Breast Cancer. In: Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Springer, 1765-1776, 2022.
- Singh B, Arlinghaus RB. Mos and the cell cycle. In: Progress in Cell Cycle Research. L. Meijer, S. Guidet, and M. Phillippe eds. Plenum Press, 251-259, 1997.
- Singh B, Hannink M, Donoghue DJ, Arlinghaus RB. p37mos-associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos. In: Yearbook of Cancer, Yearbook Medical Publishers. Yearbook Medical Publishers, 555-558, 1988.
Selected Presentations & Talks
Local Presentations
- 2018. Program update on behalf of Dr. Anthony Lucci. Conference. Program update on behalf of Dr. Anthony Lucci. Houston, TX, US.
- 2018. A usable cell culture model of resistant minimal residual disease in triple-negative inflammatory breast cancer: Mechanistic insights and evaluation of a potential therapy. Conference. A usable cell culture model of resistant minimal residual disease in triple-negative inflammatory breast cancer: Mechanistic insights and evaluation of a potential therapy. Houston, TX, US.
- 2017. Program update. Conference. Program update. Houston, TX, US.
- 2016. Targeting cancer evolution in Inflammatory Breast Cancer. Conference. Targeting cancer evolution in Inflammatory Breast Cancer. Houston, TX, US.
- 2015. Highly Adaptable Breast Cancer Cells as a Functional Model for Testing Anticancer Agents for TNBC. Conference. Highly Adaptable Breast Cancer Cells as a Functional Model for Testing Anticancer Agents for TNBC. Houston, TX, US.
Regional Presentations
- 2013. Adaptable metabolic state in cancer: translating knowledge into clinical application. Conference. Adaptable metabolic state in cancer: translating knowledge into clinical application, US.
- 2013. A new strategy for testing therapies to be effective against genome-based drivers of triple-negative breast cancer, Houston, Texas, October 4-5. Conference. A new strategy for testing therapies to be effective against genome-based drivers of triple-negative breast cancer, Houston, Texas, October 4-5, US.
- 2012. Tackling tumor heterogeneity to develop combination therapies for inflammatory breast cancer. Conference. Tackling tumor heterogeneity to develop combination therapies for inflammatory breast cancer, US.
National Presentations
- 2011. In vitro selection of metastatic breast cancer cells, Poster Presentation. Conference. In vitro selection of metastatic breast cancer cells, Poster Presentation. Orlando, FL, US.
Formal Peers
- 2015. Highly Adaptable Breast Cancer Cells as a Functional Model for Testing Anticancer Agents. Invited. Highly Adaptable Breast Cancer Cells as a Functional Model for Testing Anticancer Agents. Mumbai, IN.
- 2012. Development of a predictive in vitro assay for anti-cancer drug selection. Invited. Development of a predictive in vitro assay for anti-cancer drug selection. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | A phenotype-based preclinical model of breast cancer cells that persist in quiescence to drive cancer evolution, therapy resistance and early relapse/metastases |
| Funding Source: | DOD Breast Cancer Research Program |
| Role: | Co-I |
| ID: | BC240968 |
| Date: | 2025 - 2027 |
| Title: | A phenotype-based preclinical cell culture model of melanoma cells that persist in quiescence to drive cancer evolution, therapy resistance and early recurrence |
| Funding Source: | DOD Melanoma Research Program |
| Role: | PI |
| ID: | ME240204 |
| Date: | 2025 - 2028 |
| Title: | Modeling evolutionary fitness in resistant cancers for anti-cancer drug discovery |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP250152 |
| Date: | 2025 - 2027 |
| Title: | A phenotype-based preclinical cell culture model of melanoma cells that persist in quiescence to drive cancer evolution, therapy resistance and early recurrence |
| Funding Source: | MDACC Institutional Research Grant |
| Role: | PI |
| ID: | N/A |
| Date: | 2022 - 2024 |
| Title: | Development of liquid biopsy in Stage II and III melanoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | Liquid biopsy monitoring in Stages II b/c, and III a/b melanoma |
| Funding Source: | Melanoma Research Alliance |
| Role: | Co-I |
| Date: | 2021 - 2022 |
| Title: | Liquid biopsy monitoring in Stages II b/c, and III a/b melanoma |
| Funding Source: | MDACC |
| Role: | Co-I |
| Date: | 2020 - 2025 |
| Title: | Clinically meaningful restaging of inflammatory breast cancer with the integration of diagnostic imaging and circulating tumor cell monitoring |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA248199-01 |
| Date: | 2020 - 2023 |
| Title: | Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2020 - 2023 |
| Title: | Clinically meaningful restaging of stage I-III triple-negative breast cancer with the integration of diagnostic imaging and fluid-based tumor monitoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP200346 |
| Date: | 2019 - 2022 |
| Title: | Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-PI |
| ID: | BC181484 |
| Date: | 2018 - 2021 |
| Title: | A usable model of resistant triple-negative breast cancer cells for discovering therapies that will halt cancer recurrence and metastasis |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-PI |
| ID: | BC171298 |
| Date: | 2018 - Present |
| Title: | A usable model of highly adaptable metabolic state in triple-negative breast cancer for discovering therapies that will improve immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA225944-01 |
| Date: | 2018 - Present |
| Title: | A usable model of resistant triple-negative breast cancer cells for discovering therapies that will halt cancer recurrence and metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP180280 |
| Date: | 2016 - 2021 |
| Title: | Phase II SBIR application – Imaging of Her2-postive cancer with SUPR peptides |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | SBIR |
| Date: | 2016 - 2019 |
| Title: | Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA203878-01 |
| Date: | 2016 - 2019 |
| Title: | Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Date: | 2015 - 2018 |
| Title: | Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-PI |
| ID: | BC141729 |
| Date: | 2014 - Present |
| Title: | Grant for Rare and Aggressive Cancers (supports Morgan Welch Inflammatory Breast Cancer Research Program) |
| Funding Source: | State of Texas Grant |
| Role: | Investigator |
| Date: | 2014 - Present |
| Title: | Modeling the Roots of Therapy-resistant Triple-negative Breast Cancer for Drug Discovery by Selecting Adaptable Metabolic State in vitro |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | Investigator-initiated Research Grant |
| Date: | 2013 - 2016 |
| Title: | The Design of Novel Imaging Probes for Sulfotyrosine: Imaging of Activated CXCR4 |
| Funding Source: | DOD Idea Award, DOD Breast Cancer Research Program |
| Role: | Investigator |
| Date: | 2013 - 2016 |
| Title: | (PQD5) A predictive cell-based method for testing anti-cancer therapies |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | 1R01CA179938-01 |
| Date: | 2013 - 2013 |
| Title: | Tackling tumor heterogeneity to develop effective combination therapies for metastatic breast cancer |
| Funding Source: | Metavivor Research Grant |
| Role: | Co-PI |
| Date: | 2012 - 2017 |
| Title: | Preclinical translation of metabolic plasticity in breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1-R01-CA160525-01 |
| Date: | 2012 - 2014 |
| Title: | Development of a predictive in vitro assay for anti-cancer drug selection |
| Funding Source: | MDACC Institutional Research Grant Program (Translational Research) |
| Role: | PI |
| Date: | 2011 - 2014 |
| Title: | A novel glutamine metabolism-based strategy to investigate breast cancer metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Date: | 2010 - 2014 |
| Title: | Novel approaches for therapeutic targeting of COX-2 in breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2010 - Present |
| Title: | Functional assays to investigate links between cellular metabolism, chemotherapy-resistance, and metastasis in breast cancer |
| Funding Source: | Department of Defense (DOD) Concept Award |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | Clinical application of disseminated tumor cells in breast cancer, RC1, |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | A novel approach to evaluate targeted therapy for the eradication of breast cancer micrometastases |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| Date: | 2009 - 2014 |
| Title: | Eradication of breast cancer minimal residual disease with a bisphonsphonate and a COX-2 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R01-CA129630-01A2 |
| Date: | 2008 - 2013 |
| Title: | Promise Grant on Inflammatory Breast Cancer. Project 3: Therapeutic effects of CXCR4 inhibitors on IBC tumor xenografts, Title: Novel targets for treatment and detection of inflammatory breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Investigator |
| Date: | 2008 - 2010 |
| Title: | Identification and characterization of disseminated tumor cells in the bone marrow of breast cancer patients |
| Funding Source: | Society of Surgical Oncology Clinical Investigator |
| Role: | Investigator |
| Date: | 2008 - 2011 |
| Title: | Targeted eradication of breast cancer cells from the bone marrow and blood |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-I |
| ID: | KG071164 |
| Date: | 2008 - 2009 |
| Title: | CTCE-9908 in vivo model of inflammatory breast cancer |
| Funding Source: | Chemokine Therapeutics, Inc |
| Role: | Investigator |
| Date: | 2008 - 2010 |
| Title: | Melanoma treatment through targeted eradication of micrometastasis |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center-Center for Targeted Therapy Melanoma Grant |
| Role: | Co-I |
| Date: | 2007 - 2009 |
| Title: | Targeted therapy based on molecular characteristics of disseminated tumor cells in triple-negative breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-06-BCRP-SIA2 |
| Date: | 2007 - 2008 |
| Title: | Role of cyclooxygenase-2 in breast cancer initiating cell phenotype |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-06-BCRP-CA |
| Date: | 2006 - 2008 |
| Title: | CXCR4 as a therapeutic target in malignant melanoma |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Investigator |
| Date: | 2003 - 2008 |
| Title: | A model of COX-2 mediated bone metastasis in human breast cancer |
| Funding Source: | Department of Defense (DOD) Idea Award |
| Role: | Investigator |
| ID: | DAMD17-03-1-0669 |
Patient Reviews
CV information above last modified December 09, 2024